Bedrich L. Eckhardt
Papers
1
Total Citations
22
H-Index
1
About
Dr. Bedrich L. Eckhardt is a leading translational researcher dedicated to conquering inflammatory breast cancer (IBC), the most lethal and aggressive form of breast cancer. His work centers on developing clinically relevant models to understand IBC’s unique biology and to identify effective, targeted therapies. His landmark 2018 study, which has garnered 22 citations, introduced a groundbreaking patient-derived xenograft (PDX) ex vivo model. This model allows for the direct evaluation of tumor-specific therapies on living IBC tissue, bridging a critical gap between laboratory discovery and patient treatment. By creating this platform, Dr. Eckhardt has provided the field with an essential tool for testing novel drugs and understanding why IBC is so resistant to standard treatments. His contributions are vital for improving the dismal 62-68% five-year survival rate associated with IBC, offering new hope for personalized therapeutic strategies against this devastating disease.
Research Focus
Key Achievements
Top Papers
- 1